Novartis Canada
Novartis Canada (Novartis Pharmaceuticals Canada Inc.) is the Canadian subsidiary of Novartis AG, selling innovative specialty pharmaceuticals — Kisqali, Scemblix, Cosentyx, Pluvicto, and Lutathera — across oncology, immunology, and rare diseases, reimbursed through provincial drug programs and pCPA negotiations, and serving Canadian healthcare professionals, patients, and public payers.
- Company typePrivate
- Founded1996
- HeadquartersDorval, Canada
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What Novartis Canada does
Novartis Canada (legal entity Novartis Pharmaceuticals Canada Inc.) is the Canadian operating subsidiary of Swiss multinational Novartis AG, headquartered in Dorval, Quebec, and founded in 1996. It manufactures, registers, and distributes innovative prescription pharmaceuticals across oncology, immunology, cardiology, dermatology, rheumatology, nephrology, and hematology, employing 251–500 staff and operating bilingual (English/French) healthcare-professional portals and a medical information hotline to support clinical engagement nationwide.
Its core product portfolio centers on targeted specialty therapies: Kisqali (ribociclib, a CDK4/6 inhibitor for HR+/HER2− breast cancer), Scemblix (asciminib for chronic myeloid leukemia), Cosentyx (secukinumab, an IL-17A inhibitor for hidradenitis suppurativa, psoriasis, psoriatic arthritis, and ankylosing spondylitis), and the radioligand therapy franchise comprising Pluvicto (lutetium 177Lu vipivotide tetraxetan for PSMA-positive metastatic castration-resistant prostate cancer) and Lutathera ([177Lu]Lu-DOTA-TATE for somatostatin-receptor-positive neuroendocrine tumors). Pluvicto received Health Canada approval in August 2022 as the first targeted radioligand therapy of its kind and is delivered through specialized hospital and retail pharmacy channels. The company also runs the Novartis Pro Portal, a digital HCP education platform offering 200+ hours of microlearning content from 50+ Canadian experts across five therapeutic areas.
Revenue is generated through prescription pharmaceutical sales reimbursed primarily via Canadian public payers: pricing is negotiated centrally through the pan-Canadian Pharmaceutical Alliance (pCPA) and implemented provincially, with Ontario's FAST program now accelerating access to breakthrough cancer therapies. As of mid-2025, Pluvicto was publicly reimbursed in seven provinces (Quebec, Ontario, Alberta, British Columbia, Nova Scotia, Saskatchewan, Newfoundland and Labrador), and Cosentyx for hidradenitis suppurativa achieved first-provincial listing in Quebec. The company supplements its commercial operations with two grant programs: NOYCIA (established 2004, over $1.1 million cumulative, $50,000 CAD awarded in 2026 to ten early-career oncology researchers who present at ASCO) and the Health Equity Initiative (over $560,000 awarded in 2025 to organizations addressing systemic health disparities, with the Federal Health Minister in attendance). Leadership transitioned in December 2025 with Dimitri Gitas appointed Country President.
Novartis Canada firmographics
Firmographics- Name
- Novartis Canada
- Legal name
- Novartis Pharmaceuticals Canada Inc.
- Website
- https://novartis.ca
- Company type
- Private
- Founded year
- 1996
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Novartis Canada (Novartis Pharmaceuticals Canada Inc.) is the Canadian subsidiary of Novartis AG, selling innovative specialty pharmaceuticals — Kisqali, Scemblix, Cosentyx, Pluvicto, and Lutathera — across oncology, immunology, and rare diseases, reimbursed through provincial drug programs and pCPA negotiations, and serving Canadian healthcare professionals, patients, and public payers.
- Ownership category
- akta.pro rank
Novartis Canada industry classification
Industry- Product category
- Prescription Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Medical Oncology (HLAKAFAB)
- akta.pro secondary industry
- Specialty Pharmacy & Biologics Distribution (CRAOAHAD)
Keywords
Where Novartis Canada is headquartered
LocationHeadquarters
- HQ city
- Dorval
- HQ country
- Canada
- HQ region
- North America
Offices1 record
Markets served
Novartis Canada business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain
Revenue model
- Pharmaceutical Product Sales: Revenue generated from the sale of prescription pharmaceutical products including Kisqali, Scemblix, Cosentyx, Pluvicto, and other branded medications. Products are distributed through public reimbursement channels (provincial drug programs) and potentially private insurance.
- Public Reimbursement (Government Payer): Revenue from public drug plans including provincial reimbursement through pCPA negotiations, Ontario's FAST program, and Quebec's public drug program.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Public reimbursement pricing through provincial drug programs |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels4 records
Novartis Canada product offering
Product offeringCore offering
Novartis Canada develops, manufactures, and distributes innovative prescription pharmaceutical medicines across oncology, immunology, cardiology, dermatology, rheumatology, nephrology, and hematology. The portfolio includes targeted cancer therapies (Kisqali, Scemblix), radioligand therapies (Pluvicto, Lutathera), and IL-17A inhibitor Cosentyx, distributed primarily through provincial public drug programs and hospital/retail pharmacies under negotiated reimbursement.
Product overview
Novartis Canada operates as a diversified pharmaceutical company offering a portfolio of innovative medicines and digital health solutions. The core product portfolio includes targeted cancer therapies such as Kisqali® (ribociclib) for breast cancer, Scemblix® for chronic myeloid leukemia, Pluvicto® and Lutathera® as radioligand therapies for prostate cancer and neuroendocrine tumors respectively, and Cosentyx® (secukinumab) for inflammatory conditions. Supporting the product portfolio is the Novartis Pro Portal, a digital platform providing healthcare professionals with medical resources, clinical data, and product information. The company also administers grant programs including NOYCIA for oncology researchers and the Health Equity Initiative, reflecting its commitment to advancing cancer research and addressing health disparities in Canada.
Differentiator
Problem solved
Functional benefit
Products and services
- Kisqali (ribociclib tablets) CDK4/6 inhibitor approved for treating hormone receptor-positive, HER2-negative early and metastatic breast cancer, demonstrating 28% reduction in recurrence risk for early-stage patients at high risk of recurrence.
- Scemblix Breakthrough cancer therapy for chronic myeloid leukemia (CML), prioritized under Ontario's FAST program for expedited patient access.
- Cosentyx (secukinumab) IL-17A inhibitor for treating moderate to severe hidradenitis suppurativa (HS), psoriasis, psoriatic arthritis, and ankylosing spondylitis, publicly reimbursed across Canadian provinces.
- Pluvicto (lutetium 177Lu vipivotide tetraxetan) Targeted radioligand therapy for PSMA-positive metastatic castration-resistant prostate cancer, the first of its kind approved by Health Canada (August 2022), now publicly funded in seven provinces.
- Lutathera ([177Lu]Lu-DOTA-TATE) Approved radioligand therapy agent for advanced somatostatin receptor-positive neuroendocrine tumors.
Quantifiable outcome
- 28% reduction in recurrence risk demonstrated in clinical trials for Kisqali
- +2 more outcomes
Companies that use Novartis Canada
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles2 records
Novartis Canada technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Novartis Canada partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and strategic.
- American Society of Clinical Oncology (ASCO)coreNOYCIA winners present their research work at the ASCO Annual Meeting in Chicago on May 31, 2026, providing visibility for early-career Canadian oncology researchers.
- American Society for Radiation Oncology (ASTRO)strategicASTRO launched National Authorized User Training Centers program supported by educational grant from Novartis Pharmaceuticals Corp to expand the number of physicians certified to deliver radiopharmaceutical therapy.
- Ontario Ministry of HealthcoreOntario's new FAST program prioritizes Scemblix for public reimbursement, aiming to reduce wait times and improve treatment accessibility for patients with chronic myeloid leukemia.
- pan-Canadian Pharmaceutical Alliance (pCPA)coreNovartis Canada concluded negotiations with pCPA to secure public reimbursement of Cosentyx for hidradenitis suppurativa and continues collaboration with provincial public drug programs for timely access to innovative therapies nationwide.
- Health Equity Initiative WinnerscoreThree Canadian organizations received over $560,000 in grants to support projects addressing systemic health disparities in Canada. Federal Health Minister the Honourable Marjorie Michel attended the Montreal ceremony.
- Quebec Ministry of HealthcoreQuebec became the first province to list Pluvicto for public reimbursement, marking a significant milestone for radioligand therapy access in Canada. Pluvicto is now publicly funded in seven provinces.
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
Novartis Canada competitors and assessment
Company assessmentDirect peers
- Merck Canada: Canadian subsidiary of Merck (MSD), anchored by Keytruda in oncology — overlapping prescriber base with Kisqali, Scemblix, and Pluvicto — and competing for similar provincial reimbursement listings and FAST-program priority.
- Pfizer Canada: Canadian operations of Pfizer with a comparable diversified branded pharmaceutical portfolio spanning oncology, inflammation/immunology, and rare diseases — overlapping prescriber segments and similar pCPA pathway.
- Johnson & Johnson Innovative Medicine Canada: Canadian innovative-medicines arm of J&J, with oncology (Darzalex, Erleada, Imbruvica), immunology, and pulmonary hypertension franchises — directly competing for the same specialist prescriber base and payer budgets.
- Bayer Canada: Canadian subsidiary of Bayer, with overlapping oncology portfolio including Xofigo (radium-223) — a radiopharmaceutical therapeutic that puts Bayer in direct competition with Pluvicto and Lutathera on modality and channel.
- Bristol-Myers Squibb Canada: Canadian operations of BMS with strong oncology and hematology franchise (Opdivo, Reblozyl, Pomalyst), overlapping with Scemblix in hematology and Kisqali in breast cancer competitive sets.
- Eli Lilly Canada: Canadian subsidiary of Eli Lilly, direct competitor through Verzenio (abemaciclib) in the CDK4/6 inhibitor space where Kisqali is a flagship product, plus growing oncology and immunology portfolio.
- Roche Canada: Canadian operations of Roche, also anchored by oncology (Tecentriq, Polivy, Hemlibra, Phesgo) and competing biologics, with similar pCPA-led reimbursement model and bilingual HCP engagement.
- AstraZeneca Canada: Canadian subsidiary of AstraZeneca, with overlapping oncology footprint (Tagrisso, Imfinzi, Enhertu) and emerging radioligand therapy capability following the Fusion Pharma acquisition — a direct competitive vector against Pluvicto and Lutathera.
- Sanofi Canada: Canadian operations of Sanofi with immunology focus (Dupixent) — a direct competitor to Cosentyx in dermatology and rheumatology — plus oncology and rare disease assets that overlap with Novartis Canada's broader portfolio.
Broad incumbents
- GSK Canada: Canadian arm of GSK with broad pharma portfolio across specialty (Blenrep, Jemperli) and immunology (Benlysta) — overlapping but less oncology-heavy than Novartis Canada, making it a broader-mix competitor rather than head-to-head in core oncology.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Novartis Canada social profiles
Digital presenceNovartis Canada financial estimates
Financial estimateRevenue estimate
Valuation estimate
Novartis Canada leadership team
Management profileNumber of profiles
Profiles2 records
Novartis Canada funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Novartis Canada M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Novartis Canada
What does Novartis Canada do?
Novartis Canada develops, manufactures, and distributes innovative prescription pharmaceutical medicines across oncology, immunology, cardiology, dermatology, rheumatology, nephrology, and hematology. The portfolio includes targeted cancer therapies (Kisqali, Scemblix), radioligand therapies (Pluvicto, Lutathera), and IL-17A inhibitor Cosentyx, distributed primarily through provincial public drug programs and hospital/retail pharmacies under negotiated reimbursement.
Is Novartis Canada a public or private company?
Novartis Canada is a private company. It is classified as corporate owned and is currently operating.
When was Novartis Canada founded?
Novartis Canada was founded in 1996. It employs 251 to 500 people.
Where is Novartis Canada based?
Novartis Canada is headquartered in Dorval, Canada, in the North America region.
How does Novartis Canada make money?
Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are public Reimbursement (Government Payer).
Who are Novartis Canada's main competitors?
Direct peers on record are Merck Canada, Pfizer Canada, Johnson & Johnson Innovative Medicine Canada, Bayer Canada, Bristol-Myers Squibb Canada, Eli Lilly Canada, Roche Canada, AstraZeneca Canada and Sanofi Canada. GSK Canada is listed as a broad incumbent.
Does Novartis Canada have an API?
No public API is recorded for Novartis Canada.
What industry is Novartis Canada in?
Novartis Canada's product category is Prescription Pharmaceuticals. Its primary akta.pro industry code is HLAKAFAB, Medical Oncology, with a secondary code of CRAOAHAD, Specialty Pharmacy & Biologics Distribution. Its NAICS code is 325412 and its SIC code is 2834.